Stocks · Healthcare · Biotechnology
Turn Therapeutics Inc. TTRX
$13.33 +0.15% Close, Oct 2, 2026 · NASDAQ · Market cap $397.1M
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 116.7% in a year.
- The stock is in an uptrend: above its 200-day average for 49 trading days, with the 50-day average above the 200-day.
- The company holds net cash of $4.2M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 13%
- Accruals (lower is better)Top 9%
- Interest coverBottom 22%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 37%
- Free-cash-flow yieldTop 39%
- EBITDA / enterprise valueTop 41%
Strength and persistence of the price trend, including versus the S&P 500.
- 6-month returnTop 1%
- Distance from 52-week highBottom 29%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 10%
- Maximum drawdown, 3 yearsBottom 50%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -84.7% | — | Bottom 13% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -24.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -28.9×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.95%
- Shareholder yield
- -0.95%
- Share count change, 1 year
- +116.7%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 1 of 4
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -2.9%
- Positive 20 days after report
- 3 of 4
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | -900.0% | -6.5% | -6.8% | +26.9% | — |
| May 11, 2026 | -50.0% | +2.4% | +6.9% | +40.6% | +148.8% |
| Mar 31, 2026 | +118.6% | -0.6% | +4.3% | +11.8% | +111.8% |
| Nov 13, 2025 | -37.3% | -7.0% | -35.7% | -27.0% | -15.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.20 | -$0.02 | -900.0% | — |
| May 11, 2026 | -$0.03 | -$0.02 | -50.0% | — |
| Mar 31, 2026 | $0.01 | -$0.05 | +118.6% | — |
| Nov 13, 2025 | -$0.07 | -$0.05 | -37.3% | — |
| Sep 2, 2025 | -$0.09 | — | — | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -1.09% | — | — | Top 39% |
| Earnings yield | -2.19% | — | — | Top 37% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 112
- Days above the 200-day average
- 49
- 50-day average slope (20 days)
- +21.1%
- 200-day average slope (20 days)
- +19.0%
- Distance from 50-day average
- +20.8%
- Distance from 200-day average
- +112.1%
- RSI (14)
- 54.7
- Relative volume
- 0.76×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 95.3%
- Current drawdown from 1-year high
- -13.1%
- Maximum drawdown, 3 years
- -70.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 9, 2025 | Nov 20, 2025 | -70.5% | 30 days | 154 days (Jul 7, 2026) |
| Jul 21, 2026 | Jul 29, 2026 | -27.0% | 6 days | 7 days (Aug 7, 2026) |
| Sep 21, 2026 | Sep 25, 2026 | -18.6% | 4 days | Not yet recovered |
| Aug 12, 2026 | Aug 21, 2026 | -10.3% | 7 days | 11 days (Sep 8, 2026) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $397.1M
- EPS, diluted (TTM)
- -$0.29
- Revenue (TTM)
- $0
- 52-week range
- $2.57 – $26.50
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 |
| Operating income | -$2.3M | -$1.8M | -$5.9M |
| Net income | -$2.3M | -$1.8M | -$3.2M |
| EPS (diluted) | -$0.17 | -$0.13 | -$0.23 |
| Q2 2024 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$351,936 | -$1.2M | -$1.9M | $279,070 | -$970,972 | -$5.8M |
| EPS (diluted) | -$0.03 | -$0.09 | -$0.07 | $0.01 | -$0.03 | -$0.20 |
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Operating cash flow | -$1.4M | -$1.4M | -$2.6M |
| Capital expenditure | -$44,306 | -$99,475 | -$152,986 |
| Free cash flow | -$1.4M | -$1.5M | -$2.7M |
| Dividends paid | $0 | $0 | $0 |
| Net share buybacks | $500,000 | $1.2M | $6.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $10.3M
- Total assets
- $17.0M
- Total liabilities
- $16.3M
- Total debt
- $6.1M
- Net debt
- -$4.2M
- Shareholders’ equity
- $686,888
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 154,372
- Days to cover
- 1.14
- Change vs previous report
- +16.3%
FINRA short interest, settlement date Sep 15, 2026.